Lower Urine Tenofovir Concentrations Among Individuals Taking Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate: Implications for Point-of-Care Testing
Open Access
- 17 April 2021
- journal article
- research article
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 8 (7) , ofab200
Abstract
From directly observed therapy studies, urine tenofovir (TFV) levels were 74% lower when taking tenofovir alafenamide (TAF) vs tenofovir disoproxil fumarate. Urine TFV remains quantifiable across a range of TAF adherence patterns, but a separate point-of-care lateral flow immunoassay with a lower TFV threshold will be needed to support TAF adherence monitoring.Keywords
Funding Information
- National Institute of Mental Health
- National Institutes of Health (K23MH122286)
- National Institute of Allergy and Infectious Diseases (R01AI152119, R01 AI122298, R21 AI127200)
- Gilead Sciences (CO-US-412-399)
This publication has 12 references indexed in Scilit:
- Urine Tenofovir Concentrations Correlate With Plasma and Relate to Tenofovir Disoproxil Fumarate Adherence: A Randomized, Directly Observed Pharmacokinetic Trial (TARGET Study)Clinical Infectious Diseases, 2020
- Intracellular Tenofovir-Diphosphate and Emtricitabine-Triphosphate in Dried Blood Spots Following Tenofovir Alafenamide: The TAF-DBS StudyJAIDS Journal of Acquired Immune Deficiency Syndromes, 2020
- Urine Assay to Measure Tenofovir Concentrations in Patients Taking Tenofovir AlafenamideFrontiers in Pharmacology, 2020
- Development and validation of the first point-of-care assay to objectively monitor adherence to HIV treatment and prevention in real-time in routine settingsAIDS, 2020
- Brief Report: Urine Emtricitabine and Tenofovir Concentrations Provide Markers of Recent Antiretroviral Drug Exposure Among HIV-Negative Men Who Have Sex With MenJAIDS Journal of Acquired Immune Deficiency Syndromes, 2019
- Brief Report: Validation of a Urine Tenofovir Immunoassay for Adherence Monitoring to PrEP and ART and Establishing the Cutoff for a Point-of-Care TestJAIDS Journal of Acquired Immune Deficiency Syndromes, 2019
- Ending the HIV EpidemicJAMA, 2019
- Development and Validation of an Immunoassay for Tenofovir in Urine as a Real-Time Metric of Antiretroviral AdherenceeClinicalMedicine, 2018
- Plasma and intracellular pharmacokinetics of tenofovir in patients switched from tenofovir disoproxil fumarate to tenofovir alafenamideAIDS, 2018
- A randomized clinical pharmacokinetic trial of Tenofovir in blood, plasma and urine in adults with perfect, moderate and low PrEP adherence: the TARGET studyBMC Infectious Diseases, 2017